Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Despite being the world’s second-largest pharmaceutical market, China isn’t known for its prowess in drug innovation. The country has some of the highest incidence rates for cancer, diabetes and liver...
A virtually impenetrable middle market under the control of incumbent conglomerates is the least governable of the systemic obstacles facing private equity hopefuls in the Philippines
GGV Capital has joined a group of investors in a venture round of undisclosed size for Structo, a Singapore-based 3D printing company focused on the dental industry.
TSign – a China-based electronic signature service provider – has received RMB650 million ($92 million) in Series C funding led by Alibaba Group affiliate Ant Financial. Other investors include Gobi Partners and Eminence Ventures.